% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pulte:135966,
      author       = {D. Pulte$^*$ and J. Weberpals$^*$ and C. C. Schröder$^*$
                      and K. Emrich and B. Holleczek and A. Katalinic and S.
                      Luttmann and E. Sirri and L. Jansen$^*$ and H. Brenner$^*$},
      collaboration = {G. C. S. W. Group},
      title        = {{S}urvival of patients with hepatobiliary tract and
                      duodenal cancer sites in {G}ermany and the {U}nited {S}tates
                      in the early 21st century.},
      journal      = {International journal of cancer},
      volume       = {143},
      number       = {2},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2018-00703},
      pages        = {324 - 332},
      year         = {2018},
      abstract     = {Hepatobiliary tract cancers (HBTCs) are a heterogeneous
                      group of cancers with high mortality. Because most of these
                      cancers, with the exception of hepatocellular carcinoma
                      (HCC), are rare, few data are available concerning the
                      population level survival expectations of patients with
                      HBTC. Here, we describe survival of patients with HBTC in
                      Germany with comparison to survival in the US. Therefore,
                      data were extracted from 12 databases in Germany and the
                      Surveillance, Epidemiology and End Results (SEER13) database
                      in the US. Period analysis and modeled period analysis were
                      used to calculate 5-year relative survival estimates for
                      patients with HBTC diagnosed from 1997 to 2013. HCC was the
                      most common HBTC in each database, accounting for over 1/3
                      of HBTC in Germany and about half of cases in the US.
                      Overall age adjusted 5-year relative survival for HBTC in
                      2006-2013 was $19.1\%$ in Germany and $20.6\%$ in the US.
                      Five-year relative survival increased by $3.8\%$ units in
                      Germany and $4.5\%$ units in the US between 2002-2005 and
                      2010-2013. Five-year relative survival for individual types
                      of HBTC ranged from $9.8\%$ in Germany and $2.9\%$ in the US
                      for not otherwise specified biliary tract cancers to
                      $44.4\%$ and $50.1\%,$ respectively, in Germany and the US
                      for duodenal cancers. In conclusion, survival for HBTC
                      remains poor in both Germany and the US, although a small
                      increase in survival in the past decade was observed.
                      Further work to find better treatment options for HBTC is
                      needed to improve survival.},
      cin          = {C070 / G110 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)G110-20160331 /
                      I:(DE-He78)L101-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29479701},
      doi          = {10.1002/ijc.31322},
      url          = {https://inrepo02.dkfz.de/record/135966},
}